Balinotti 2015.

Methods	Prospective, randomised, double‐blind controlled trial. Duration: 1 year.
Participants	Children over 6 years of age with a diagnosis of CF made by 6 months of age. 19 participants randomised: 3 excluded, 9 participants in HS group, 7 participants in IS group.
Interventions	Intervention: HS 3% plus 0.25 mg/kg salbutamol 2x daily. Control: IS 0.9% plus 0.25 mg/kg salbutamol 2x daily.
Outcomes	Primary outcome: maximal flow at functional residual capacity (change from baseline). Secondary outcomes: pulmonary exacerbations, respiratory rate, nutritional status, adverse events.
Notes